The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.
Glenmark will be responsible for manufacturing and supplying Ryaltris while Lotus will commercialize the drug in the targeted markets. In lieu of this, Glenmark will receive an upfront payment as well as regulatory and sales-based payments from Lotus.
The company’s revenue from operations rose 59.3% yoy to Rs21.12cr in Q3FY22.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
